A large genetic study finds Epstein-Barr virus targets B-cells and may help trigger multiple sclerosis, adding weight to the virus–autoimmunity connection.
Most people carry Epstein-Barr virus (EBV), but a new large-scale genetic study suggests it doesn’t affect everyone in the same way—and that difference could matter for multiple sclerosis.
The findings add to a growing body of evidence that EBV helps shape the immune pathways involved in multiple sclerosis (MS). an autoimmune disease in which the immune system mistakenly attacks parts of the central nervous system.. In the study. researchers analyzed genetic and medical data from more than 600. 000 people and looked for relationships between EBV “load” in the body and inherited genetic variants tied to MS risk.
EBV is widely known as the cause of glandular fever (“mono”).. After infection. the virus can persist in the body for years. which is one reason it has been hard to study: with so many infected people. the challenge is identifying who will develop MS and why.. Earlier population work made the broad connection clearer—people who have had EBV are more likely to develop MS than those who haven’t.. The new study pushes the question further by focusing on the mechanisms: which immune cells are involved. and how genetics may influence viral behavior.
MS affects nearly 2 million people globally and can produce symptoms ranging from vision problems and balance difficulties to tremor.. Under the hood, the disease involves multiple immune cell types, including T-cells that can enter the brain and drive damage.. Over time, symptoms can fluctuate for some people or gradually worsen for others.. Understanding what tips the immune system from “normal antiviral response” toward chronic self-attack has been a central challenge in MS research.
A striking pattern in the study was the distribution of EBV DNA in blood samples.. While most people carried some viral genetic material, a small fraction carried disproportionately more.. That mattered because the researchers then searched for inherited genetic variants associated with vulnerability to EBV—essentially. the genetic differences that influence how much EBV ends up circulating or persisting in the body.. They identified 39 genomic regions linked to having higher EBV DNA.
Crucially. about a third of the genetic signals related to EBV were also connected to MS risk. including risk for a more severe form of the disease.. That overlap is important because it strengthens the idea that EBV isn’t merely correlated with MS. but is part of a shared biological pathway influenced by genetics.. At the same time. the direction of the relationship is not uniform: some variants mapped to both higher EBV load and higher MS risk. but others pointed to lower EBV levels alongside higher MS risk.. In other words. the immune system’s response to the virus—and the genetic “settings” that shape that response—may determine which individuals are pushed toward MS.
The study then narrowed its focus to B-cells, a key immune cell type involved in producing antibodies.. Researchers examined hundreds of thousands of B-cells from dozens of participants and found a substantial number infected by EBV.. Those infected cells showed abnormal gene activity tied to both higher EBV DNA and increased MS risk.. They also appeared to activate immune signaling pathways that can turn on T-cells—the same T-cells implicated in the inflammatory damage seen in MS.
This is where the story becomes more than a statistical link.. Multiple sclerosis is often framed as a disorder of immune misdirection. but this research suggests an immune “chain reaction” could be involved: EBV living in B-cells. altered gene expression in those cells. and downstream activation of T-cells.. It also helps explain why some people may mount stronger antibody responses that better control viral persistence. while others may have responses that fail to keep EBV in check.
For readers, the practical significance is twofold.. First. it offers a clearer target for prevention strategies—because if viral control affects downstream immune behavior. then reducing viral influence might lower risk for some individuals.. Second. it raises the stakes for personalized medicine: genetics may help identify who is more likely to have high EBV activity and immune activation patterns that resemble pathways leading to MS.
There is also an important caution built into the findings.. The study suggests different genetic variants may influence MS risk through different routes—either by driving an exacerbated immune response or by weakening the ability to manage the virus.. That complexity matters for treatment design.. A therapy that targets EBV might help in one subgroup. while another subgroup might remain at risk through immune changes that have already become self-sustaining.
In the longer term, EBV-directed interventions are an active area of interest.. Immune-based approaches that target EBV have shown promise in research. and EBV vaccines are being developed. with the idea that they could potentially reduce viral persistence and thus lower downstream immune complications.. Yet translating prevention into real-world benefit for MS remains uncertain—particularly because MS may not always depend on the virus forever.. As some researchers involved in earlier discussions have cautioned. once MS is established. EBV might still contribute—or it might become less central as the disease process continues on its own.
Still, the direction of travel is clear.. Misryoum’s takeaway from this large genetic study is that EBV. especially its relationship with B-cells and T-cell activation. is moving from “suspected trigger” to a more testable biological pathway.. The next steps will likely involve proving causality in more detail. clarifying which immune patterns predict disease. and determining whether EBV-targeted prevention can meaningfully change MS outcomes for the right people at the right time.